Qualité de vie des malades atteints de schizophrénie : étude de 100 cas

Zouari, L.; Thabet, J. Ben; Elloumi, Z.; Elleuch, Mouna; Zouari, N.; Maâlej, M.

doi:10.1016/j.encep.2011.03.005

Cited by 11 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The direction of the “expected” path was based on theoretical assumptions. Because antipsychotics affect insight [42], QoL [43,44], depression [45], and suicide [46], chlorpromazine equivalent doses were added as a covariate. Negative, positive and general schizophrenic symptomatology were added as covariates to control for their potential confounding effect in the relationships between insight, QoL, depression, and suicide [12,47,48].…”

Section: Methodsmentioning

confidence: 99%

Modeling the Longitudinal Effects of Insight on Depression, Quality of Life and Suicidality in Schizophrenia Spectrum Disorders: Results from the FACE-SZ Cohort

Ehrminger

Urbach

Passerieux

et al. 2019

JCM

View full text Add to dashboard Cite

Background: Up to half of the patients with schizophrenia attempt suicide during their lifetime. Better insight is associated with better functioning but also with increased suicidality. The direction of the relationship between insight and suicidality is not clear, hence we aimed to provide new elements using structural equation modeling. Methods: Insight, quality of life (QoL), depression, and suicidality were measured at baseline and at 12 months in individuals with schizophrenia spectrum disorders. The relationships between these variables were investigated by latent difference score models, controlling for chlorpromazine doses, positive and negative symptoms, and general psychopathology. Results: 738 patients were included, and 370 completed the study. Baseline levels of insight predicted changes in suicidality, whereas baseline levels of suicidality did not predict changes in insight, suggesting that better insight underlies suicidality and predicts its worsening. Our results suggest this temporal sequence: better insight → worse QoL → increased depression → increased suicidality, while insight also affects the three variables in parallel. Conclusion: Better insight predicts a worsening of QoL, depression and suicidality. These findings contribute to our global understanding of the longitudinal influence of insight on suicidality. We advocate that insight-targeted interventions should not be proposed without the monitoring of depression and suicide prevention.

show abstract

Section: Methodsmentioning

confidence: 99%

Modeling the Longitudinal Effects of Insight on Depression, Quality of Life and Suicidality in Schizophrenia Spectrum Disorders: Results from the FACE-SZ Cohort

Ehrminger

Urbach

Passerieux

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Antipsychotics may impact differently on QoL, with studies suggesting that atypical antipsychotics may have a more positive impact on QoL than typical antipsychotics, possibly because of a slightly favorable effect on negative symptoms and better subjective tolerability. 32 – 34 In addition, the mode of administration, frequency, and ease of use all play a major role in the overall effectiveness of antipsychotic therapy. 35 A recent time trade-off study showed that longer injection intervals were associated with improved HRQoL (utility), suggesting that the use of long-acting injectable (LAI) antipsychotics may improve adherence, leading to improved QoL.…”

Section: Objectivementioning

confidence: 99%

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics

Bartolomeis¹,

Fagiolini²,

Vaggi³

et al. 2016

NDT

View full text Add to dashboard Cite

PurposeThis survey of Italian psychiatrists was conducted to better define drivers of schizophrenia treatment choice in real-life practice, particularly for use of long-acting injectable (LAI) antipsychotics.MethodsBetween October 15 and December 15, 2014, 1,000 surveys were sent to psychiatrists who treat schizophrenic patients; 709 completed questionnaires were analyzed (71% response rate).ResultsThe two most important factors determining therapy success were efficacy (75% of responses) and tolerability (45%) followed by global functioning (24%) and quality of life (17%). LAI antipsychotics were most often used to facilitate regular treatment monitoring (49%), and 41% of psychiatrists thought that patients with low adherence who had failed oral therapy were well-suited for LAI antipsychotics. Only 4% of respondents saw LAI antipsychotics as appropriate for patients without other therapeutic options.ConclusionAlthough efficacy and tolerability were the most common factors used to evaluate treatment success in schizophrenia, psychiatrists also consider QoL and global functioning to be important.

show abstract

Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs

Araújo

Dantas²,

Nascimento

et al. 2014

Psychiatr Q

View full text Add to dashboard Cite

This cross-sectional study compared the effects of treatment with atypical antipsychotic drugs on quality of life (QoL) and side effects in 218 patients with schizophrenia attending the ambulatory services of psychiatric in Rio Grande do Norte, Brazil. Socio-economic variables were compared. The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson-Angus Scale. Data were analysed using the χ (2) test and Student's t test, with a significance level of 5 %. Average monthly household incomes in the medication groups were 1.1-2.1 minimum wages ($339-$678). UKU Scale scores showed significant differences in side effects, mainly, clozapine, quetiapine and ziprasidone (p < 0.05). EQ-5D scores showed that all drugs except olanzapine significantly impacted mobility (p < 0.05), and proportions of individuals reporting problems in other dimensions were high: 63.6 % of clozapine users reported mobility problems, 63.7 and 56.3 % of clozapine and ziprasidone users, respectively, had difficulties with usual activities, 68.8 and 54.5 % of ziprasidone and clozapine users, respectively, experienced pain and/or discomfort, and 72.8 % of clozapine users reported anxiety and/or depression. Psychiatric, neurological, and autonomous adverse effects, as well as other side effects, were prevalent in users of atypical antipsychotic drugs, especially clozapine and ziprasidone. Olanzapine had the least side effects. QoL was impacted by side effects and economic conditions in all groups. Thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations.

show abstract

Qualité de vie des malades atteints de schizophrénie : étude de 100 cas

Cited by 11 publications

References 19 publications

Modeling the Longitudinal Effects of Insight on Depression, Quality of Life and Suicidality in Schizophrenia Spectrum Disorders: Results from the FACE-SZ Cohort

Modeling the Longitudinal Effects of Insight on Depression, Quality of Life and Suicidality in Schizophrenia Spectrum Disorders: Results from the FACE-SZ Cohort

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics

Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs

Contact Info

Product

Resources

About